Mironid Secures, 39.9M Series B to Accelerate Kidney Disease Clinical Trials

Glasgow-based Mironid has successfully secured, 39.9 million in Series B funding to accelerate the clinical development of its lead drug candidate. The therapeutic is specifically designed to address Autosomal Dominant Polycystic Kidney Disease (ADPKD), a…